Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,099 Shares

Key Points

• Royalty Pharma EVP Marshall Urist sold 9,099 shares on July 1 at an average price of $55.88, generating about $508,452. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
• Urist has made multiple recent insider sales, including similar transactions on June 24, May 20, and May 14, totaling tens of thousands of shares sold over the past few weeks.
• Royalty Pharma’s stock rose to $57.77 in Thursday trading, near its 52-week high of $57.80, while the company continues to show strong analyst support and recently paid a quarterly dividend of $0.235 per share.

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 9,099 shares of the business's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $55.88, for a total value of $508,452.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Urist also recently made the following trade(s):

• On Wednesday, June 24th, Marshall Urist sold 9,098 shares of Royalty Pharma stock. The shares were sold at an average price of $55.18, for a total transaction of $502,027.64.
• On Wednesday, May 20th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The stock was sold at an average price of $52.75, for a total transaction of $721,831.00.
• On Thursday, May 14th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The stock was sold at an average price of $53.06, for a total transaction of $726,073.04.

Royalty Pharma Price Performance

NASDAQ:RPRX traded up $1.99 during mid-day trading on Thursday, reaching $57.77. The stock had a trading volume of 3,227,665 shares, compared to its average volume of 3,705,712. Royalty Pharma PLC has a 12 month low of $34.08 and a 12 month high of $57.80. The stock has a market capitalization of $33.27 billion, a PE ratio of 39.30, a P/E/G ratio of 1.54 and a beta of 0.43. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. The stock has a 50-day simple moving average of $53.23 and a two-hundred day simple moving average of $47.02.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.08. The firm had revenue of $630.58 million during the quarter, compared to analysts' expectations of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. On average, equities analysts anticipate that Royalty Pharma PLC will post 5.05 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were issued a dividend of $0.235 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.6%. Royalty Pharma's payout ratio is 63.95%.

Institutional Trading of Royalty Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RPRX. LM Advisors LLC bought a new position in Royalty Pharma during the 4th quarter worth approximately $26,000. Lloyd Advisory Services LLC. acquired a new position in shares of Royalty Pharma in the 4th quarter worth approximately $30,000. Private Trust Co. NA boosted its stake in shares of Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 288 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Royalty Pharma by 173.4% in the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 437 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its position in shares of Royalty Pharma by 66.4% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company's stock worth $43,000 after buying an additional 446 shares during the period. Institutional investors and hedge funds own 54.35% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on RPRX shares. UBS Group raised their price objective on Royalty Pharma from $51.00 to $57.00 and gave the company a "buy" rating in a research note on Tuesday, April 21st. Morgan Stanley increased their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a report on Friday, April 10th. Wall Street Zen upgraded shares of Royalty Pharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday, May 9th. Weiss Ratings lowered shares of Royalty Pharma from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, May 15th. Finally, Citigroup upped their price objective on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Royalty Pharma has an average rating of "Buy" and a consensus price target of $53.71.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.